Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterogénica

@article{NezCorts2014ConsensoDE,
  title={Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterog{\'e}nica},
  author={Jes{\'u}s Mill{\'a}n N{\'u}{\~n}ez-Cort{\'e}s and Juan Pedro-Botet and {\'A}ngel Brea-Hernando and {\'A}ngel D{\'i}az-Rodr{\'i}guez and Pedro Gonz{\'a}lez-Santos and Antonio Hern{\'a}ndez-Mijares and Teresa Mantilla-Morat{\'o} and Xavier Pint{\'o}-Sala and Rafael Sim{\'o}},
  journal={Revista Espanola De Cardiologia},
  year={2014},
  volume={67},
  pages={36-44}
}
[Introduction. Justification].
  • J. Núñez-Cortés
  • Medicine
    Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
  • 2014
La guía europea de dislipemia. Fortalezas y debilidades
La guia conjunta de la Sociedad Europea de Cardiologia y la European Atherosclerosis Society para el manejo de la dislipemia incluye varios aspectos de interes clinico: la estratificacion del riesgo
...
1
2
3
4
...

References

SHOWING 1-10 OF 39 REFERENCES
Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)
TLDR
The European Society of Cardiology Committee for Practice Guidelines for Cardiology (CPG) concluded that cardiology practice guidelines should be considered as a totality, not as a collection of recommendations for individual patients.
Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.
TLDR
The application of the Beers criteria and other tools for identifying potentially inappropriate medication use will continue to enable providers to plan interventions for decreasing both drug-related costs and overall costs and thus minimize drug- related problems.
Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system.
TLDR
Searching additional databases beyond the Cochrane Library, MEDLINE, EMBASE and SCI, plus BIOSIS limited to meeting abstracts only, was seldom found to be effective in retrieving additional studies for inclusion in the clinical and cost-effectiveness sections of TARs.
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
TLDR
Metabolic syndrome components identify higher CVD risk in individuals with type 2 diabetes, so the absolute benefits of fenofibrate are likely to be greater when metabolic syndrome features are present.
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
TLDR
These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians but also specialists from lipid clinics or metabolic units who are dealing with dyslipIDAemias that are more difficult to classify and treat.
Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies
TLDR
Based on combined data from prospective studies, triglyceride is a risk factor for cardiovascular disease for both men and women in the general population, independent of HDL cholesterol.
Systematic review of endoscopic sinus surgery for nasal polyps.
TLDR
The majority of studies report that symptoms improve following FESS with relatively few complications; however, only a small proportion of evidence is comparative.
Effects of combination lipid therapy in type 2 diabetes mellitus.
TLDR
The routine use of combination therapy with fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with type 2 diabetes does not support the routine use.
...
1
2
3
4
...